Giuseppe Ruggieri

Giuseppe Ruggieri

Auto-generated profile, based on publicly available information

Giuseppe Ruggieri

Dipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur‐Fondazione Cenci Bolognetti “Sapienza” Università di Roma Rome Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Antonella MessoreAntonella Messore
Antonella Messore
Paolo MalunePaolo Malune
Paolo Malune
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
DIDavide Ialongo
Davide Ialongo
Roberta CostiRoberta Costi
Roberta Costi
It has been more than four years since the first report of SARS-CoV-2, and humankind has experienced a pandemic with an unprecedented impact. Moreover, the new variants have made the situation even worse. Among viral enzymes, the SARS-CoV-2 main protease (Mpro) has been deemed a promising drug target vs. COVID-19. Indeed, Mpro is a pivotal enzyme for viral replication, and it is highly conserved within coronaviruses. It showed a high extent of conservation of the protease residues essential to the enzymatic activity, emphasizing its potential as a drug target to develop wide-spectrum antiviral agents effective not only vs. SARS-CoV-2 variants but also against other coronaviruses. Even though the FDA-approved drug nirmatrelvir, a Mpro inhibitor, has boosted the antiviral therapy for the treatment of COVID-19, the drug shows several drawbacks that hinder its clinical application. Herein, we report the synthesis of new thiazolidine-4-one derivatives endowed with inhibitory potencies in the micromolar range against SARS-CoV-2 Mpro. In silico studies shed light on the key structural requirements responsible for binding to highly conserved enzymatic residues, showing that the thiazolidinone core acts as a mimetic of the Gln amino acid of the natural substrate and the central role of the nitro-substituted aromatic portion in establishing π-π stacking interactions with the catalytic His-41 residue.

20 May 2025 in ChemMedChem
Verified
Journal Article
Open access
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
RERoberta Emmolo
Roberta Emmolo
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
DADonatella Amatore
Donatella Amatore
SMStefania Maloccu
Stefania Maloccu
Roberta CostiRoberta Costi
Roberta Costi
It has been more than four years since the first report of SARS‐CoV‐2, the virus responsible for the coronavirus disease 2019 (COVID‐19) pandemic, the scientific community is focused on vaccine development in an exceptionally rapid time frame, as well as the evaluation of a wide range of potential treatments in clinical trials, a few of which have also reached the market. However, these drugs are characterized by several limits (including low response to treatment in some patients, low effectiveness against the new variants, severe side effects, etc.), thus underscoring the need to speed up the research. Among potential antiviral targets, the SARS‐CoV‐2 nonstructural protein 13 (nsp13) is highly promising thanks to its pivotal role in viral replication. Pursuing the studies on the development of nsp13 inhibitors, herein, the design, synthesis, and biological evaluation of new SARS‐CoV‐2 nsp13 inhibitors are reported. In general, the newly designed dikehexenoic derivatives are proven active against both the enzymatic activities showing measurable IC50 under 30 μM concentration, while the diketobutanoic series shows less promising results. Moreover, the tested compounds are capable of blocking viral replication without exerting cytotoxicity. Docking studies predict their binding into an allosteric pocket within the RecA2 domain.

5 August 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
AAAurora Albano
Aurora Albano
GRGiuseppe Ruggieri
Giuseppe Ruggieri
AMAntonella Messore
Antonella Messore
Roberta CostiRoberta Costi
Roberta Costi

12 August 2025 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
AAAurora Albano
Aurora Albano
RERoberta Emmolo
Roberta Emmolo
RSRiccardo De Santis
Riccardo De Santis
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
Roberta CostiRoberta Costi
Roberta Costi
COVID-19 pandemic stimulated tremendous efforts to develop therapeutic strategies targeting SARS-CoV-2, leading to the evaluation of a wide range of potential treatments in clinical trials. However, effective therapeutics remain elusive when the development of new variants and the limits of antiviral drugs is considered. Therefore, the development of antiviral drugs against SARS-CoV-2 is of paramount importance. Among potential drug targets, the SARS-CoV-2 nsp13 is highly attractive thanks to its pivotal role in viral replication. Pursuing our studies on the development of nsp13 inhibitors, in this work we describe the design, synthesis, and biological evaluation of novel inhibitors targeting SARS-CoV-2 nsp13. The newly designed N-benzyl indole derivatives were active against both enzymatic activities showing measurable IC50 under 30 μM concentration, while N-alkyl derivatives showed less promising results. Interestingly, the tested compounds blocked viral replication with no cytotoxicity. Docking studies predicted their binding into an allosteric conserved site located in the RecA2 domain.

9 June 2025 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
NGNadia Garibaldi
Nadia Garibaldi
DIDavide Ialongo
Davide Ialongo
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
VTValeria Tudino
Valeria Tudino
Roberta CostiRoberta Costi
Roberta Costi
Terminal deoxynucleotidyl transferase (TdT) is overexpressed in some cancer types, where it drives the mutagenic repair of double strand breaks through non canonical non-homologous end joining pathway. The TdT enzyme belongs to the X family of polymerases, together with the DNA polymerase λ (pol λ) and β (pol β). However, TdT exclusively displays template-independent nucleotide polymerisation. Pursuing our studies in developing TdT inhibitors, herein we deepened the structure-activity relationships of new structural analogues of our previously identified hit compounds. The diketo hexenoic acid derivatives here analysed showed high selectivity towards TdT and inhibition potencies spanning from the low micromolar range to the nanomolar. Docking studies highlighted the chemical features involved in the TdT binding, well contributing to the rationalisation of the structural requirements needed for the enzymatic inhibition.

22 August 2026 in ChemMedChem
Verified
Journal Article
Open access
PDF file
Francesco SaccolitiFrancesco Saccoliti
Francesco Saccoliti
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
ECEmanuele Cara
Emanuele Cara
LZLaura Zarbo
Laura Zarbo
AMAntonella Messore
Antonella Messore
RSRoberto Di Santo
Roberto Di Santo
Given its pivotal role in the viral life cycle, blocking integrase (IN) through IN strand transfer inhibitors (INSTIs) represented a breakthrough in the treatment of HIV infection, establishing these antiretroviral regimens as first‐line options against AIDS. However, the onset of drug‐resistant strains has challenged the efficacy of INSTIs, demanding new efforts in the search for therapeutic tools that work through alternative modes of action. In this context, the discovery of allosteric IN inhibitors (ALLINIs) has highlighted new opportunities to target IN beyond its active site, enhancing antiviral efficacy and the genetic barrier to resistance. Extensive drug discovery campaigns have resulted in the development of effective ALLINIs with both in vitro and in vivo efficacy, two of which are advancing in clinical trials as next‐generation therapeutic tools. Nevertheless, advancements in structural biology have critically aided in elucidating the underlying effects of ALLINIs, highlighting a complex, multimodal mode of action that ultimately yields defects in virion maturation. This review focuses on ALLINIs, providing a comprehensive overview of major drug discovery efforts devoted to this field, with an emphasis on the medicinal chemistry and structural biology findings that have revealed unprecedented opportunities for developing innovative and effective anti‐HIV drugs.